The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A study to evaluate the safety, tolerability, and efficacy of IBI939 in combination with sintilimab in patients with previously untreated locally advanced unresectable or metastatic PD-L1–selected non–small-cell lung cancer (NSCLC): Updated efficacy and safety results.
 
Chunjiao Wu
No Relationships to Disclose
 
Baogang Liu
No Relationships to Disclose
 
Lin Wu
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Hengrui Pharmaceutical; Innovent Biologics; Lilly; Merck; MSD; Pfizer; Roche
 
Tongmei Zhang
No Relationships to Disclose
 
Ke Wang
No Relationships to Disclose
 
Liyun Miao
No Relationships to Disclose
 
Jingxun Wu
No Relationships to Disclose
 
Huijuan Wang
No Relationships to Disclose
 
Jian Fang
No Relationships to Disclose
 
Xingya Li
No Relationships to Disclose
 
Wei Zhang
No Relationships to Disclose
 
Yanping Hu
No Relationships to Disclose
 
Xiaodong Mei
No Relationships to Disclose
 
Yong Song
No Relationships to Disclose
 
Jing Zhu
No Relationships to Disclose
 
Ying Xin
No Relationships to Disclose
 
Yue He
Employment - Innovent Biologics
 
Yuling Chen
Employment - Innovent Biologics
 
Jiawei Ye
Employment - Innovent Biologics
 
Ying Cheng
No Relationships to Disclose